Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 14, 2026, 10:04 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 33 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Clopidogrel 300 mg Clear all
Terminated Phase 1 Interventional

Efficacy of Activated Recombinant Human Factor VII in Healthy Volunteers Treated for Punch Biopsy Mediated Bleeding

NCT01561950
View directory record Official record
Conditions
Haemostasis, Healthy
Interventions
eptacog alfa (activated), clopidogrel, placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Neptune City, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 22, 2016 · Synced Sep 14, 2026, 10:04 AM EDT
Not listed Phase 3 Interventional

Safety and Efficacy of Low-Dose Ticagrelor in Chinese Patients With NSTE-ACS

NCT02415803
View directory record Official record
Conditions
Non ST Segment Elevation Acute Coronary Syndrome
Interventions
low-dose ticagrelor, conventional-dose ticagrelor, Clopidogrel
Drug
Lead sponsor
First Affiliated Hospital of Harbin Medical University
Other
Eligibility
18 Years to 75 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2014
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Apr 13, 2015 · Synced Sep 14, 2026, 10:04 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug Interaction Study of Clopidogrel and Rosuvastatin

NCT01469416
View directory record Official record
Conditions
Healthy
Interventions
Rosuvastatin, Clopidogrel
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 17, 2014 · Synced Sep 14, 2026, 10:04 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

The Impact of Grapefruit Juice on the Response to Clopidogrel

NCT00817999
View directory record Official record
Conditions
Healthy
Interventions
Grapefruit juice, Clopidogrel 75 mg/day, Clopidogrel 300 mg
Dietary Supplement · Drug
Lead sponsor
Creighton University
Other
Eligibility
19 Years to 40 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 30, 2012 · Synced Sep 14, 2026, 10:04 AM EDT
Completed Phase 2 Interventional Results available

A Trial of CS-747 (Prasugrel) Compared With Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention (PCI)

NCT00059215
View directory record Official record
Conditions
Cardiovascular Diseases, Heart Diseases
Interventions
Prasugrel (CS-747), Clopidogrel
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
905 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 24, 2010 · Synced Sep 14, 2026, 10:04 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug Interaction Study of MGL-3196 With Clopidogrel

NCT04671069
View directory record Official record
Conditions
Healthy
Interventions
MGL-3196, Clopidogrel
Drug
Lead sponsor
Madrigal Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Dec 27, 2020 · Synced Sep 14, 2026, 10:04 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Antithrombotic Effects of Ticagrelor Versus Clopidogrel

NCT01642238
View directory record Official record
Conditions
Acute Coronary Syndrome
Interventions
Ticagrelor + ASA + Bivalirudin, Clopidogrel + ASA + Bivalirudin
Drug
Lead sponsor
Juan J Badimon
Other
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 10, 2016 · Synced Sep 14, 2026, 10:04 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Interaction Study of Clopidogrel 300/75 mg Given Alone or Concomitantly With Omeprazole 80 mg in Healthy Subjects

NCT01129375
View directory record Official record
Conditions
Healthy
Interventions
clopidogrel, placebo, omeprazole
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 65 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 14, 2011 · Synced Sep 14, 2026, 10:04 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Aspirin Resistance and Stroke Risk: Platelet Function Analysis in Patients With Ischemic Events

NCT01586975
View directory record Official record
Conditions
Stroke, Myocardial Infarctions
Interventions
Clopidogrel, Aspirin 81 mg, Aspirin >300 mg
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 30, 2015 · Synced Sep 14, 2026, 10:04 AM EDT
Completed Not applicable Interventional Results available

The Effect of Clopidogrel on Coated-Platelets in Patients Undergoing Cardiac Catheterization

NCT00644657
View directory record Official record
Conditions
Coronary Artery Disease, Chest Pain
Interventions
Clopidogrel
Drug
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years to 65 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Oct 6, 2011 · Synced Sep 14, 2026, 10:04 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Food Effect Study on Pharmacodynamic and Bioavailability of Clopidogrel 300/75 mg in Healthy Subjects

NCT01129271
View directory record Official record
Conditions
Healthy
Interventions
clopidogrel, Matching placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 14, 2011 · Synced Sep 14, 2026, 10:04 AM EDT
Not listed Phase 2Phase 3 Interventional

Half-dose Ticagrelor Overcomes High-dose Clopidogrel in Acute Coronary Syndrome Patients With High On-Clopidogrel Platelet Reactivity

NCT03062462
View directory record Official record
Conditions
Coronary Artery Disease, Clopidogrel, Poor Metabolism of
Interventions
Clopidogrel, ticagrelor
Drug
Lead sponsor
First Affiliated Hospital of Harbin Medical University
Other
Eligibility
18 Years to 75 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Havertown, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 6, 2018 · Synced Sep 14, 2026, 10:04 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Determining Genetic Role in Treatment Response to Anti-Platelet Interventions (The PAPI Study)

NCT00799396
View directory record Official record
Conditions
Platelet Aggregation Inhibitors, Coronary Heart Disease
Interventions
Clopidogrel, Aspirin
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
20 Years and older
Enrollment
682 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2012
U.S. locations
1
States / cities
Lancaster, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 23, 2022 · Synced Sep 14, 2026, 10:04 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Clopidogrel Pharmacogenetics (PGX) Bench to Bedside

NCT01341600
View directory record Official record
Conditions
Metabolism of Clopidogrel
Interventions
Clopidogrel, Omeprazole/Clopidogrel
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
20 Years to 70 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Lancaster, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 29, 2024 · Synced Sep 14, 2026, 10:04 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Interaction Between ACT-246475 and Clopidogrel, Prasugrel, and Ticagrelor in Healthy Subjects

NCT03430661
View directory record Official record
Conditions
Healthy
Interventions
ACT-246475, Clopidogrel, Prasugrel, Placebo, Ticagrelor
Drug
Lead sponsor
Viatris Innovation GmbH
Industry
Eligibility
18 Years to 65 Years
Enrollment
77 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 2, 2025 · Synced Sep 14, 2026, 10:04 AM EDT
Completed Phase 3 Interventional Results available

A Comparison of Prasugrel and Clopidogrel in Acute Coronary Syndrome Subjects

NCT00699998
View directory record Official record
Conditions
Acute Coronary Syndrome
Interventions
Clopidogrel, Prasugrel, Commercially-available Aspirin
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
9,326 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
165
States / cities
Birmingham, Alabama • Huntsville, Alabama • Glendale, Arizona + 162 more
Source: ClinicalTrials.gov public record
Updated May 6, 2013 · Synced Sep 14, 2026, 10:04 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Interaction Study of Clopidogrel 300/75 mg Given Alone or With Omeprazole 80 mg 12 Hours Apart in Healthy Subjects

NCT01129388
View directory record Official record
Conditions
Healthy
Interventions
clopidogrel, Placebo, omeprazole
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 65 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 14, 2011 · Synced Sep 14, 2026, 10:04 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Evaluating Effect of Esomeprazole, Omeprazole or Lansoprazole on the Pharmacodynamics (PD) and Pharmacokinetics (PK) of Clopidogrel

NCT01147588
View directory record Official record
Conditions
Healthy
Interventions
lansoprazole, omeprazole, esomeprazole, clopidogrel
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
149 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 27, 2011 · Synced Sep 14, 2026, 10:04 AM EDT
Terminated Phase 2 Interventional Results available

A Study of the Effects of Inhibiting Platelet Function on Circulating Cancer Cells in Breast Cancer Patients

NCT00263211
View directory record Official record
Conditions
Breast Neoplasms
Interventions
Plavix, Aspirin
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 14, 2017 · Synced Sep 14, 2026, 10:04 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Pharmacokinetic Study on the Effect of LY2216684 on the Active Metabolite of Clopidogrel

NCT01263093
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Clopidogrel, LY2216684
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 21, 2018 · Synced Sep 14, 2026, 10:04 AM EDT
Withdrawn Phase 4 Interventional

Comparing Ticagrelor and Clopidogrel Pharmacodynamics After Thrombolysis

NCT02048085
View directory record Official record
Conditions
Acute ST Segment Elevation Myocardial Infarction, Acute Coronary Syndrome
Interventions
Ticagrelor, Clopidogrel
Drug
Lead sponsor
Medical Center of South Arkansas
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
El Dorado, Arkansas
Source: ClinicalTrials.gov public record
Updated Apr 3, 2018 · Synced Sep 14, 2026, 10:04 AM EDT
Completed Phase 3 Interventional Results available

A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention (PCI) (CHAMPION PHOENIX)

NCT01156571
View directory record Official record
Conditions
Atherosclerosis, Percutaneous Coronary Intervention, Acute Coronary Syndrome
Interventions
cangrelor P2Y12 (platelet) inhibitor, Clopidogrel - 300 or 600 mg (study arm), Clopidogrel 600 mg post cangrelor
Drug
Lead sponsor
The Medicines Company
Industry
Eligibility
18 Years and older
Enrollment
11,145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Anderson, South Carolina
Source: ClinicalTrials.gov public record
Updated Feb 3, 2014 · Synced Sep 14, 2026, 10:04 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess Administration of an Oral Anti-thrombotic With Antiplatelet Therapy in Healthy Subjects

NCT03698513
View directory record Official record
Conditions
Healthy Volunteers
Interventions
BMS-986177, Placebo (for BMS-986177), Clopidogrel, Aspirin
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 55 Years
Enrollment
113 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Sep 28, 2021 · Synced Sep 14, 2026, 10:04 AM EDT
Completed Phase 2 Interventional Results available

Escalating Clopidogrel by Involving a Genetic Strategy - Thrombolysis In Myocardial Infarction 56

NCT01235351
View directory record Official record
Conditions
Myocardial Infarction, Percutaneous Coronary Intervention
Interventions
Clopidogrel
Drug
Lead sponsor
The TIMI Study Group
Other
Eligibility
18 Years to 75 Years
Enrollment
335 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 14, 2019 · Synced Sep 14, 2026, 10:04 AM EDT